George Crotts

Title: The Innovative Contributions of George Crotts

Introduction

George Crotts is a notable inventor based in Kintnersville, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral peptide dosage forms. His innovative approach has the potential to enhance the delivery and effectiveness of peptide-based medications.

Latest Patents

Crotts holds a patent for an oral peptide pharmaceutical dosage form and method of production. This patent describes a pharmaceutical composition designed for oral delivery of a peptide, structured as a lamination with at least two layers. The first layer contains a pharmaceutically acceptable pH-lowering agent, while the second layer includes a therapeutically effective amount of the peptide. Additionally, the composition incorporates an absorption enhancer to improve the bioavailability of the peptide, which is typically found in the second layer. An enteric coating surrounds the lamination, ensuring the stability and effectiveness of the dosage form. In a preferred embodiment, the peptide is salmon calcitonin, the pH-lowering agent is citric acid, and the absorption enhancer is lauroyl l-carnitine.

Career Highlights

George Crotts is associated with Unigene Laboratories Inc., where he has been instrumental in advancing pharmaceutical innovations. His work focuses on improving the delivery mechanisms of peptide-based therapies, which are crucial for treating various medical conditions.

Collaborations

Crotts has collaborated with notable colleagues, including Isaac Ghebre-Sellassie and Ashlesh Sheth. These partnerships have fostered a collaborative environment that encourages innovation and the development of effective pharmaceutical solutions.

Conclusion

George Crotts exemplifies the spirit of innovation in the pharmaceutical industry through his groundbreaking work on oral peptide dosage forms. His contributions are paving the way for more effective treatments and improved patient outcomes.